Los Angeles Times (12.15.11) - Monday, December 19, 2011
Results from a new study involving nearly 40,000 women found
that human papillomavirus (HPV) DNA testing in addition to Pap
smear prevented more cervical cancer cases than Pap smear
The trial randomized women in the Netherlands, ages 29-56,
into two groups at baseline: One received HPV and cytology co-
testing, and the other group received cytology testing alone.
Five years later, both groups received co-testing.
Women co-tested at baseline had fewer cases of cervical
abnormalities and cancers than women who had only Pap smears.
"Our results lend support to the use of HPV DNA testing for
all women aged 29 years and older," concluded study leader Dr.
Chris J.L.M. Meijer, of Amsterdam-based VU University Medical
Center, and colleagues.
The full study, "Human Papillomavirus Testing for the
Detection of High-Grade Cervical Intraepithelial Neoplasia and
Cancer: Final Results of the POBASCAM Randomized Controlled
Trial," was published online ahead of the regular issue of
Lancet Oncology (2011;doi:10.1016/S1470-2045(11)70296-0).